175 related articles for article (PubMed ID: 10411640)
1. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.
Lövgren J; Airas K; Lilja H
Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640
[TBL] [Abstract][Full Text] [Related]
2. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation.
Deperthes D; Frenette G; Brillard-Bourdet M; Bourgeois L; Gauthier F; Tremblay RR; Dubé JY
J Androl; 1996; 17(6):659-65. PubMed ID: 9016396
[TBL] [Abstract][Full Text] [Related]
3. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor.
Malm J; Hellman J; Hogg P; Lilja H
Prostate; 2000 Oct; 45(2):132-9. PubMed ID: 11027412
[TBL] [Abstract][Full Text] [Related]
5. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.
Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
Prostate; 1998 Jan; 34(1):44-50. PubMed ID: 9428387
[TBL] [Abstract][Full Text] [Related]
6. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.
Lövgren J; Rajakoski K; Karp M; Lundwall â ; Lilja H
Biochem Biophys Res Commun; 1997 Sep; 238(2):549-55. PubMed ID: 9299549
[TBL] [Abstract][Full Text] [Related]
7. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
Charlesworth MC; Young CY; Miller VM; Tindall DJ
J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
[TBL] [Abstract][Full Text] [Related]
8. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2.
Bourgeois L; Brillard-Bourdet M; Deperthes D; Juliano MA; Juliano L; Tremblay RR; Dubé JY; Gauthier F
J Biol Chem; 1997 Nov; 272(47):29590-5. PubMed ID: 9368023
[TBL] [Abstract][Full Text] [Related]
9. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids.
Lövgren J; Valtonen-André C; Marsal K; Lilja H; Lundwall A
J Androl; 1999; 20(3):348-55. PubMed ID: 10386814
[TBL] [Abstract][Full Text] [Related]
10. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Denmeade SR; Lou W; Lövgren J; Malm J; Lilja H; Isaacs JT
Cancer Res; 1997 Nov; 57(21):4924-30. PubMed ID: 9354459
[TBL] [Abstract][Full Text] [Related]
11. Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor.
Kise H; Nishioka J; Kawamura J; Suzuki K
Eur J Biochem; 1996 May; 238(1):88-96. PubMed ID: 8665956
[TBL] [Abstract][Full Text] [Related]
12. Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen.
Jonsson M; Linse S; Frohm B; Lundwall A; Malm J
Biochem J; 2005 Apr; 387(Pt 2):447-53. PubMed ID: 15563730
[TBL] [Abstract][Full Text] [Related]
13. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2.
Mikolajczyk SD; Millar LS; Marker KM; Grauer LS; Goel A; Cass MM; Kumar A; Saedi MS
Eur J Biochem; 1997 Jun; 246(2):440-6. PubMed ID: 9208936
[TBL] [Abstract][Full Text] [Related]
14. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT
Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422
[TBL] [Abstract][Full Text] [Related]
15. Purification of enzymatically active kallikrein hK2 from human seminal plasma.
Frenette G; Deperthes D; Tremblay RR; Lazure C; Dubé JY
Biochim Biophys Acta; 1997 Feb; 1334(1):109-15. PubMed ID: 9042371
[TBL] [Abstract][Full Text] [Related]
16. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
Int J Cancer; 1999 May; 81(3):438-42. PubMed ID: 10209959
[TBL] [Abstract][Full Text] [Related]
17. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase.
Takayama TK; McMullen BA; Nelson PS; Matsumura M; Fujikawa K
Biochemistry; 2001 Dec; 40(50):15341-8. PubMed ID: 11735417
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.
Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ
Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585
[TBL] [Abstract][Full Text] [Related]
19. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.
Rittenhouse HG; Finlay JA; Mikolajczyk SD; Partin AW
Crit Rev Clin Lab Sci; 1998 Aug; 35(4):275-368. PubMed ID: 9759557
[TBL] [Abstract][Full Text] [Related]
20. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology.
Cloutier SM; Chagas JR; Mach JP; Gygi CM; Leisinger HJ; Deperthes D
Eur J Biochem; 2002 Jun; 269(11):2747-54. PubMed ID: 12047384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
